Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation
Pancreatic cancer is a highly metastatic cancer with an exceptionally poor prognosis. Despite development of different drugs and combined therapies, advances in survival rate still remain low and slow, mainly due to the invasiveness and late diagnosis. Therefore, it is crucial to find an effective treatment for invasiveness. The first-line therapy for pancreatic cancer is gemcitabine. Everolimus is another drug with benefits in gemcitabine-refractory metastasis. Rgs16 has a role in inhibition of pancreatic cancer migration and invasion. Accordingly, we aimed to investigate to which extent a combination of everolimus and gemcitabine is effective in killing highly metastatic pancreatic cancer cells and alter the expression of Rgs16 indicating its usefulness in invasiveness. Gemcitabine, everolimus, and a combination of both drugs were added to cultured Panc-1 cells. The cell killing effects of the drugs were tested through alamar blue assay and cell count. The expression of Rgs16 gene and protein was measured by qPCR and Western blotting. This study showed that a combination of everolimus and gemcitabine is more potent than everolimus, which is more effective than gemcitabine, in killing pancreatic cancer cells. However, Rgs16 as a marker of invasion was very low in Panc-1 cells and the drugs were not effective in altering Rgs16 gene expression or protein level. Although this may suggest that Panc-1 is a very invasive cell line and these drugs are not effective in highly metastatic cases, the cell line might be resistant to Rgs16 expression due to its specific mutations.
KeywordsPancreatic cancer Gemcitabine Everolimus Rgs16
We thank Dr. Thomas M. Wilkie for discussions.
This study was funded by the School of Veterinary Medicine, Shiraz University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
- Oberstein PE, Saif MW (2011) First-line treatment for advanced pancreatic cancer. JOP J Pancreas 12:96–100Google Scholar
- Ocal O, Pashkov V, Kollipara RK, Zolghadri Y, Cruz VH, Hale MA, Heath BR, Artyukhin AB, Christie AL, Tsoulfas P, Lorens JB, Swift GH, Brekken RA, Wilkie TM (2015) A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis Model Mech 8:1201–1211CrossRefPubMedPubMedCentralGoogle Scholar
- Strober W (2001) Trypan blue exclusion test of cell viability. Current Protoc Immunol A3:B. 1-A3–B. B. 3Google Scholar
- Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1117CrossRefPubMedPubMedCentralGoogle Scholar
- Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M et al (2016) Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 34:3906–3913Google Scholar